Malic acidCAS# 6915-15-7 |
- DL-Malic acid
Catalog No.:BCN9917
CAS No.:617-48-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 6915-15-7 | SDF | Download SDF |
| PubChem ID | 525 | Appearance | Powder |
| Formula | C4H6O5 | M.Wt | 134.09 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-hydroxybutanedioic acid | ||
| SMILES | C(C(C(=O)O)O)C(=O)O | ||
| Standard InChIKey | BJEPYKJPYRNKOW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Malic acid is a dicarboxylic acid that is naturally found in fruits such as apples and pears. It plays a role in many sour or tart foods. Malic acid supplementation may be useful for conservative treatment of calcium renal stone disease by virtue of its capacity to induce these effects. |
| Targets | Calcium Channel |
| In vitro | Efficacy of malic acid against Listeria monocytogenes attached to poultry skin during refrigerated storage.[Pubmed: 23776283]Poult Sci. 2013 Jul;92(7):1936-41.This work evaluated the effect of Malic acid washing on the growth of Listeria monocytogenes on poultry legs stored at 4°C for 8 d. |
| In vivo | Malic acid supplementation increases urinary citrate excretion and urinary pH: implications for the potential treatment of calcium oxalate stone disease.[Pubmed: 24059642]J Endourol. 2014 Feb;28(2):229-36.Raising urinary pH and citrate excretion with alkali citrate therapy has been a widely used treatment in calcium nephrolithiasis. Citrate lowers ionized Ca(+2) concentrations and inhibits calcium salt precipitation. Conservative alternatives containing citrate such as fruit juices have been investigated and recommended. Any compound that induces systemic alkalosis will increase citraturia. Malate, a polycarboxylic anion like citrate, is a potential candidate for chelating Ca(+2) and for inducing systemic alkalinization. We undertook to investigate these possibilities.
|
Malic acid Dilution Calculator
Malic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 7.4577 mL | 37.2884 mL | 74.5768 mL | 149.1536 mL | 186.4419 mL |
| 5 mM | 1.4915 mL | 7.4577 mL | 14.9154 mL | 29.8307 mL | 37.2884 mL |
| 10 mM | 0.7458 mL | 3.7288 mL | 7.4577 mL | 14.9154 mL | 18.6442 mL |
| 50 mM | 0.1492 mL | 0.7458 mL | 1.4915 mL | 2.9831 mL | 3.7288 mL |
| 100 mM | 0.0746 mL | 0.3729 mL | 0.7458 mL | 1.4915 mL | 1.8644 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Aromadendrin 7-O-rhamnoside
Catalog No.:BCN8114
CAS No.:69135-41-7
- Fiacitabine
Catalog No.:BCC1574
CAS No.:69123-90-6
- Moracin D
Catalog No.:BCN4255
CAS No.:69120-07-6
- Moracin C
Catalog No.:BCN4254
CAS No.:69120-06-5
- 16-Hydroxy-8(17),13-labdadien-15,16-olid-19-oic acid
Catalog No.:BCN1378
CAS No.:691009-85-5
- Acetoxyisovalerylalkannin
Catalog No.:BCN3007
CAS No.:69091-17-4
- Demanyl phosphate
Catalog No.:BCN1796
CAS No.:6909-62-2
- 2-Caren-10-ol
Catalog No.:BCN4253
CAS No.:6909-19-9
- 4'-Prenyloxyresveratrol
Catalog No.:BCN2937
CAS No.:69065-16-3
- Peonidin-3-O-glucoside chloride
Catalog No.:BCN3028
CAS No.:6906-39-4
- Delphinidin-3-O-glucoside chloride
Catalog No.:BCN3020
CAS No.:6906-38-3
- Nedocromil
Catalog No.:BCC5283
CAS No.:69049-73-6
- Tigloylgomisin P
Catalog No.:BCN6926
CAS No.:69176-51-8
- Gomisin N
Catalog No.:BCN2271
CAS No.:69176-52-9
- (2S,3R,E)-2-Amino-4-heptadecene-1,3-diol
Catalog No.:BCN1765
CAS No.:6918-48-5
- Nesbuvir
Catalog No.:BCC1796
CAS No.:691852-58-1
- (±)-Hexanoylcarnitine chloride
Catalog No.:BCC6680
CAS No.:6920-35-0
- 2'-Hydroxy-4'-methylacetophenone
Catalog No.:BCN7751
CAS No.:6921-64-8
- Osthol hydrate
Catalog No.:BCN1377
CAS No.:69219-24-5
- Pinoresinol 4-O-beta-D-glucopyranoside
Catalog No.:BCN1376
CAS No.:69251-96-3
- 1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid
Catalog No.:BCN7205
CAS No.:69251-99-6
- N-Benzylcinchonidinium chloride
Catalog No.:BCC9094
CAS No.:69257-04-1
- Harpagide
Catalog No.:BCN4996
CAS No.:6926-08-5
- 8-O-Acetylharpagide
Catalog No.:BCN4256
CAS No.:6926-14-3
Malic acid supplementation increases urinary citrate excretion and urinary pH: implications for the potential treatment of calcium oxalate stone disease.[Pubmed:24059642]
J Endourol. 2014 Feb;28(2):229-36.
BACKGROUND AND PURPOSE: Raising urinary pH and citrate excretion with alkali citrate therapy has been a widely used treatment in calcium nephrolithiasis. Citrate lowers ionized Ca(+2) concentrations and inhibits calcium salt precipitation. Conservative alternatives containing citrate such as fruit juices have been investigated and recommended. Any compound that induces systemic alkalosis will increase citraturia. Malate, a polycarboxylic anion like citrate, is a potential candidate for chelating Ca(+2) and for inducing systemic alkalinization. We undertook to investigate these possibilities. MATERIALS AND METHODS: Theoretical modeling of Malic acid's effects on urinary Ca(+2) concentration and supersaturation (SS) of calcium salts was achieved using the speciation program JESS. Malic acid (1200 mg/day) was ingested for 7 days by eight healthy subjects. Urines (24 hours) were collected at baseline and on day 7. They were analyzed for routine lithogenic components, including pH and citrate. Chemical speciation and SS were calculated in both urines. RESULTS: Modeling showed that complexation between calcium and malate at physiological concentrations of the latter would have no effect on SS. Administration of the supplement induced statistically significant increases in pH and citraturia. The calculated concentration of Ca(+2) and concomitant SS calcium oxalate (CaOx) decreased after supplementation, but these were not statistically significant. SS for the calcium phosphate salts hydroxyapatite and tricalcium phosphate increased significantly as a consequence of the elevation in pH, but values for brushite and octacalcium phosphate did not change significantly. CONCLUSIONS: We speculate that consumption of Malic acid induced systemic alkalinization leading to reduced renal tubular reabsorption and metabolism of citrate, and an increase in excretion of the latter. The decrease in SS(CaOx) was caused by enhanced complexation of Ca(+2) by citrate. We conclude that Malic acid supplementation may be useful for conservative treatment of calcium renal stone disease by virtue of its capacity to induce these effects.
Efficacy of malic acid against Listeria monocytogenes attached to poultry skin during refrigerated storage.[Pubmed:23776283]
Poult Sci. 2013 Jul;92(7):1936-41.
This work evaluated the effect of Malic acid washing on the growth of Listeria monocytogenes on poultry legs stored at 4 degrees C for 8 d. Fresh inoculated chicken legs were dipped into a 1 or 2% Malic acid solution (vol/vol) for 5 min or distilled water (control). Surface pH values, sensorial characteristics (odor, color, texture, and overall appearance) and L. monocytogenes, mesophile, psychrotroph, and Enterobacteriaceae counts were evaluated after treatment (d 0) and after 1, 3, 6, and 8 d of storage at 4 degrees C. Legs washed with 2% Malic acid showed a significant (P < 0.05) inhibitory effect on L. monocytogenes compared with control legs, with a decrease of about 1.66 log units after treatment. Sensory quality was not adversely affected by Malic acid. Treatments with Malic acid reduced bacterial growth and preserved reasonable sensorial quality after storage at 4 degrees C for 6 d. This study demonstrates that, although Malic acid did reduce populations of L. monocytogenes on poultry, it did not completely inactivate the pathogen. The application of Malic acid may be used as an additional hurdle contributing to extend the shelf life of raw poultry.
